Cargando…

Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences

PURPOSE: Sensitive methods for risk stratification, monitoring therapeutic efficacy, and early relapse detection may have a major impact on treatment decisions and patient management for stage III colorectal cancer patients. Beyond assessing the predictive power of postoperative ctDNA detection, we...

Descripción completa

Detalles Bibliográficos
Autores principales: Henriksen, Tenna Vesterman, Tarazona, Noelia, Frydendahl, Amanda, Reinert, Thomas, Gimeno-Valiente, Francisco, Carbonell-Asins, Juan Antonio, Sharma, Shruti, Renner, Derrick, Hafez, Dina, Roda, Desamparados, Huerta, Marisol, Roselló, Susana, Madsen, Anders Husted, Løve, Uffe S., Andersen, Per Vadgaard, Thorlacius-Ussing, Ole, Iversen, Lene Hjerrild, Gotschalck, Kåre Andersson, Sethi, Himanshu, Aleshin, Alexey, Cervantes, Andres, Andersen, Claus Lindbjerg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401484/
https://www.ncbi.nlm.nih.gov/pubmed/34625408
http://dx.doi.org/10.1158/1078-0432.CCR-21-2404
_version_ 1784772977551736832
author Henriksen, Tenna Vesterman
Tarazona, Noelia
Frydendahl, Amanda
Reinert, Thomas
Gimeno-Valiente, Francisco
Carbonell-Asins, Juan Antonio
Sharma, Shruti
Renner, Derrick
Hafez, Dina
Roda, Desamparados
Huerta, Marisol
Roselló, Susana
Madsen, Anders Husted
Løve, Uffe S.
Andersen, Per Vadgaard
Thorlacius-Ussing, Ole
Iversen, Lene Hjerrild
Gotschalck, Kåre Andersson
Sethi, Himanshu
Aleshin, Alexey
Cervantes, Andres
Andersen, Claus Lindbjerg
author_facet Henriksen, Tenna Vesterman
Tarazona, Noelia
Frydendahl, Amanda
Reinert, Thomas
Gimeno-Valiente, Francisco
Carbonell-Asins, Juan Antonio
Sharma, Shruti
Renner, Derrick
Hafez, Dina
Roda, Desamparados
Huerta, Marisol
Roselló, Susana
Madsen, Anders Husted
Løve, Uffe S.
Andersen, Per Vadgaard
Thorlacius-Ussing, Ole
Iversen, Lene Hjerrild
Gotschalck, Kåre Andersson
Sethi, Himanshu
Aleshin, Alexey
Cervantes, Andres
Andersen, Claus Lindbjerg
author_sort Henriksen, Tenna Vesterman
collection PubMed
description PURPOSE: Sensitive methods for risk stratification, monitoring therapeutic efficacy, and early relapse detection may have a major impact on treatment decisions and patient management for stage III colorectal cancer patients. Beyond assessing the predictive power of postoperative ctDNA detection, we explored the added benefits of serial analysis: assessing adjuvant chemotherapy (ACT) efficacy, early relapse detection, and ctDNA growth rates. EXPERIMENTAL DESIGN: We recruited 168 patients with stage III colorectal cancer treated with curative intent at Danish and Spanish hospitals between 2014 and 2019. To quantify ctDNA in plasma samples (n = 1,204), 16 patient-specific somatic single-nucleotide variants were profiled using multiplex-PCR, next-generation sequencing. RESULTS: Detection of ctDNA was a strong recurrence predictor postoperatively [HR = 7.0; 95% confidence interval (CI), 3.7–13.5; P < 0.001] and directly after ACT (HR = 50.76; 95% CI, 15.4–167; P < 0.001). The recurrence rate of postoperative ctDNA-positive patients treated with ACT was 80% (16/20). Only patients who cleared ctDNA permanently during ACT did not relapse. Serial ctDNA assessment after the end of treatment was similarly predictive of recurrence (HR = 50.80; 95% CI, 14.9–172; P < 0.001), and revealed two distinct rates of exponential ctDNA growth, slow (25% ctDNA-increase/month) and fast (143% ctDNA-increase/month; P < 0.001). The ctDNA growth rate was prognostic of survival (HR = 2.7; 95% CI, 1.1–6.7; P = 0.039). Serial ctDNA analysis every 3 months detected recurrence with a median lead-time of 9.8 months compared with standard-of-care computed tomography. CONCLUSIONS: Serial postoperative ctDNA analysis has a strong prognostic value and enables tumor growth rate assessment. The novel combination of ctDNA detection and growth rate assessment provides unique opportunities for guiding decision-making. See related commentary by Morris and George, p. 438
format Online
Article
Text
id pubmed-9401484
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Association for Cancer Research
record_format MEDLINE/PubMed
spelling pubmed-94014842023-01-05 Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences Henriksen, Tenna Vesterman Tarazona, Noelia Frydendahl, Amanda Reinert, Thomas Gimeno-Valiente, Francisco Carbonell-Asins, Juan Antonio Sharma, Shruti Renner, Derrick Hafez, Dina Roda, Desamparados Huerta, Marisol Roselló, Susana Madsen, Anders Husted Løve, Uffe S. Andersen, Per Vadgaard Thorlacius-Ussing, Ole Iversen, Lene Hjerrild Gotschalck, Kåre Andersson Sethi, Himanshu Aleshin, Alexey Cervantes, Andres Andersen, Claus Lindbjerg Clin Cancer Res Precision Medicine and Imaging PURPOSE: Sensitive methods for risk stratification, monitoring therapeutic efficacy, and early relapse detection may have a major impact on treatment decisions and patient management for stage III colorectal cancer patients. Beyond assessing the predictive power of postoperative ctDNA detection, we explored the added benefits of serial analysis: assessing adjuvant chemotherapy (ACT) efficacy, early relapse detection, and ctDNA growth rates. EXPERIMENTAL DESIGN: We recruited 168 patients with stage III colorectal cancer treated with curative intent at Danish and Spanish hospitals between 2014 and 2019. To quantify ctDNA in plasma samples (n = 1,204), 16 patient-specific somatic single-nucleotide variants were profiled using multiplex-PCR, next-generation sequencing. RESULTS: Detection of ctDNA was a strong recurrence predictor postoperatively [HR = 7.0; 95% confidence interval (CI), 3.7–13.5; P < 0.001] and directly after ACT (HR = 50.76; 95% CI, 15.4–167; P < 0.001). The recurrence rate of postoperative ctDNA-positive patients treated with ACT was 80% (16/20). Only patients who cleared ctDNA permanently during ACT did not relapse. Serial ctDNA assessment after the end of treatment was similarly predictive of recurrence (HR = 50.80; 95% CI, 14.9–172; P < 0.001), and revealed two distinct rates of exponential ctDNA growth, slow (25% ctDNA-increase/month) and fast (143% ctDNA-increase/month; P < 0.001). The ctDNA growth rate was prognostic of survival (HR = 2.7; 95% CI, 1.1–6.7; P = 0.039). Serial ctDNA analysis every 3 months detected recurrence with a median lead-time of 9.8 months compared with standard-of-care computed tomography. CONCLUSIONS: Serial postoperative ctDNA analysis has a strong prognostic value and enables tumor growth rate assessment. The novel combination of ctDNA detection and growth rate assessment provides unique opportunities for guiding decision-making. See related commentary by Morris and George, p. 438 American Association for Cancer Research 2022-02-01 2021-10-08 /pmc/articles/PMC9401484/ /pubmed/34625408 http://dx.doi.org/10.1158/1078-0432.CCR-21-2404 Text en ©2021 The Authors; Published by the American Association for Cancer Research https://creativecommons.org/licenses/by-nc-nd/4.0/This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.
spellingShingle Precision Medicine and Imaging
Henriksen, Tenna Vesterman
Tarazona, Noelia
Frydendahl, Amanda
Reinert, Thomas
Gimeno-Valiente, Francisco
Carbonell-Asins, Juan Antonio
Sharma, Shruti
Renner, Derrick
Hafez, Dina
Roda, Desamparados
Huerta, Marisol
Roselló, Susana
Madsen, Anders Husted
Løve, Uffe S.
Andersen, Per Vadgaard
Thorlacius-Ussing, Ole
Iversen, Lene Hjerrild
Gotschalck, Kåre Andersson
Sethi, Himanshu
Aleshin, Alexey
Cervantes, Andres
Andersen, Claus Lindbjerg
Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences
title Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences
title_full Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences
title_fullStr Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences
title_full_unstemmed Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences
title_short Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences
title_sort circulating tumor dna in stage iii colorectal cancer, beyond minimal residual disease detection, toward assessment of adjuvant therapy efficacy and clinical behavior of recurrences
topic Precision Medicine and Imaging
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401484/
https://www.ncbi.nlm.nih.gov/pubmed/34625408
http://dx.doi.org/10.1158/1078-0432.CCR-21-2404
work_keys_str_mv AT henriksentennavesterman circulatingtumordnainstageiiicolorectalcancerbeyondminimalresidualdiseasedetectiontowardassessmentofadjuvanttherapyefficacyandclinicalbehaviorofrecurrences
AT tarazonanoelia circulatingtumordnainstageiiicolorectalcancerbeyondminimalresidualdiseasedetectiontowardassessmentofadjuvanttherapyefficacyandclinicalbehaviorofrecurrences
AT frydendahlamanda circulatingtumordnainstageiiicolorectalcancerbeyondminimalresidualdiseasedetectiontowardassessmentofadjuvanttherapyefficacyandclinicalbehaviorofrecurrences
AT reinertthomas circulatingtumordnainstageiiicolorectalcancerbeyondminimalresidualdiseasedetectiontowardassessmentofadjuvanttherapyefficacyandclinicalbehaviorofrecurrences
AT gimenovalientefrancisco circulatingtumordnainstageiiicolorectalcancerbeyondminimalresidualdiseasedetectiontowardassessmentofadjuvanttherapyefficacyandclinicalbehaviorofrecurrences
AT carbonellasinsjuanantonio circulatingtumordnainstageiiicolorectalcancerbeyondminimalresidualdiseasedetectiontowardassessmentofadjuvanttherapyefficacyandclinicalbehaviorofrecurrences
AT sharmashruti circulatingtumordnainstageiiicolorectalcancerbeyondminimalresidualdiseasedetectiontowardassessmentofadjuvanttherapyefficacyandclinicalbehaviorofrecurrences
AT rennerderrick circulatingtumordnainstageiiicolorectalcancerbeyondminimalresidualdiseasedetectiontowardassessmentofadjuvanttherapyefficacyandclinicalbehaviorofrecurrences
AT hafezdina circulatingtumordnainstageiiicolorectalcancerbeyondminimalresidualdiseasedetectiontowardassessmentofadjuvanttherapyefficacyandclinicalbehaviorofrecurrences
AT rodadesamparados circulatingtumordnainstageiiicolorectalcancerbeyondminimalresidualdiseasedetectiontowardassessmentofadjuvanttherapyefficacyandclinicalbehaviorofrecurrences
AT huertamarisol circulatingtumordnainstageiiicolorectalcancerbeyondminimalresidualdiseasedetectiontowardassessmentofadjuvanttherapyefficacyandclinicalbehaviorofrecurrences
AT rosellosusana circulatingtumordnainstageiiicolorectalcancerbeyondminimalresidualdiseasedetectiontowardassessmentofadjuvanttherapyefficacyandclinicalbehaviorofrecurrences
AT madsenandershusted circulatingtumordnainstageiiicolorectalcancerbeyondminimalresidualdiseasedetectiontowardassessmentofadjuvanttherapyefficacyandclinicalbehaviorofrecurrences
AT løveuffes circulatingtumordnainstageiiicolorectalcancerbeyondminimalresidualdiseasedetectiontowardassessmentofadjuvanttherapyefficacyandclinicalbehaviorofrecurrences
AT andersenpervadgaard circulatingtumordnainstageiiicolorectalcancerbeyondminimalresidualdiseasedetectiontowardassessmentofadjuvanttherapyefficacyandclinicalbehaviorofrecurrences
AT thorlaciusussingole circulatingtumordnainstageiiicolorectalcancerbeyondminimalresidualdiseasedetectiontowardassessmentofadjuvanttherapyefficacyandclinicalbehaviorofrecurrences
AT iversenlenehjerrild circulatingtumordnainstageiiicolorectalcancerbeyondminimalresidualdiseasedetectiontowardassessmentofadjuvanttherapyefficacyandclinicalbehaviorofrecurrences
AT gotschalckkareandersson circulatingtumordnainstageiiicolorectalcancerbeyondminimalresidualdiseasedetectiontowardassessmentofadjuvanttherapyefficacyandclinicalbehaviorofrecurrences
AT sethihimanshu circulatingtumordnainstageiiicolorectalcancerbeyondminimalresidualdiseasedetectiontowardassessmentofadjuvanttherapyefficacyandclinicalbehaviorofrecurrences
AT aleshinalexey circulatingtumordnainstageiiicolorectalcancerbeyondminimalresidualdiseasedetectiontowardassessmentofadjuvanttherapyefficacyandclinicalbehaviorofrecurrences
AT cervantesandres circulatingtumordnainstageiiicolorectalcancerbeyondminimalresidualdiseasedetectiontowardassessmentofadjuvanttherapyefficacyandclinicalbehaviorofrecurrences
AT andersenclauslindbjerg circulatingtumordnainstageiiicolorectalcancerbeyondminimalresidualdiseasedetectiontowardassessmentofadjuvanttherapyefficacyandclinicalbehaviorofrecurrences